abrdn plc — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions.
BiotechMedical DevicesDedham, US
Thurein Htoo(Executive Officer, Director)Fred Guerard(President & Chief Executive Officer)Barbara Wirostko(Executive Officer)
BoardWende Hutton(Director)inRonald M. Hunt(Director)Andrew Danielson(Director)
Co-investorsCanaan PartnersCorrelation VenturesMayo Clinic VenturesNew Leaf Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.